Sentences with phrase «gemcitabine in»

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study.

These findings support the use of gemcitabine in this setting,» the authors conclude.

Not exact matches

Certain types of bacteria make an enzyme that inactivates the drug gemcitabine, researchers report in the Sept. 15 Science.

In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic canceIn a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancein pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancer.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

By using «gemcitabine» chemotherapy to target cancer cells, and a form of vitamin A to target the surrounding stromal cells, the combined approach led to a reduction in cancer cell proliferation and invasion.

That allowed tumor cells to survive gemcitabine treatment in lab dishes and mouse studies, Leore Geller of the Weizmann Institute of Science in Rehovot, Israel, and colleagues discovered.

The current standard of care for advanced pancreatic cancer — a combination of nab - paclitaxel and gemcitabine — was developed by TGen and the HonorHealth Research Institute, and approved by the U.S. Food and Drug Administration in 2013.

The research team evaluated the combination of the biologic therapy brentuximab vedotin (Adcetris), a monoclonal antibody - drug conjugate, with the chemotherapy drug gemcitabine (Gemzar) in 42 pediatric and young - adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.

The addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival and progression free survival by 21 % and 16 %, respectively, as compared to chemotherapy alone in patients whose tumours expressed the EGFR protein.

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

By contrast, a signal of tumor activity increased sixty-fold in mice treated with the widely used chemotherapy drug gemcitabine.

The findings suggest that therapies combining these microRNAs and gemcitabine could improve our ability to treat pancreatic cancer, and measurement of microRNA levels could also provide a guide to the prognosis in such cases.

The study used a well - known line of pancreatic cancer cells (AsPC - 1) in the laboratory and assessed how well this grew when treated with either the chemotherapy drug gemcitabine or different levels of commercially available chokeberry extract alone, and when treated with a combination of gemcitabine and chokeberry extract.

Gemcitabine is used on bladder, pancreas and ovary cancer, whilst DON has been tested in clinical trials.

In the trial one group of patients received gemcitabine chemotherapy through a drip, as well as a course of IMM - 101 injections.

Researchers used the mice to show that pemetrexed and gemcitabine worked against human group 3 tumors and that the drugs could be used in combination with existing chemotherapy agents to boost treatment effectiveness without undue risk.

In further experiments, Straussman showed that antibiotics stopped bacteria with the long form from destroying gemcitabine (Science, doi.org/cc5n).

No safety concerns were identified in previous studies of pemetrexed and gemcitabine for treatment in children with other cancers.

Also, there was no significant difference in overall survival with gemcitabine (13.6 months) compared with gemcitabine plus erlotinib (11.9 months).

Based on results from this and previous studies, pemetrexed and gemcitabine were included in a St. Jude - led multicenter clinical trial of children and adolescents newly diagnosed with medulloblastoma.

Researchers demonstrated that the drugs pemetrexed and gemcitabine killed cells from mouse and human brain tumors, called group 3 medulloblastoma, growing in the laboratory.

Helmut Oettle, M.D., Ph.D., of the Charite - Universitatsmedizin Berlin, Germany, and colleagues conducted follow - up of a randomized trial that previously reported improvement in disease - free survival with adjuvant (in addition to surgery) gemcitabine therapy to determine if this treatment improved overall survival.

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survivaIn a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survivain the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survival.

The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.

BMS - 754807, a Small - Molecule Inhibitor of Insulin - like Growth Factor - 1 Receptor / Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Comparative benefits of Nab - paclitaxel over gemcitabine or polysorbate - based docetaxel in experimental pancreatic cancer.

Increased Survival in Pancreatic Cancer with nab - Paclitaxel plus Gemcitabine

This result therefore indicates that combined rituximab and gemcitabine could be an alternative approach in patients with posttransplant lymphoproliferative disease.

In - vivo treatments of xenografted tumors showed significant tumor growth inhibition induced either by rituximab or gemcitabine alone and an impressive efficacy of combined treatment.

The targeted anti-cancer drug erlotinib (Tarceva ®) has also demonstrated a small improvement in advanced pancreatic cancer survival when used in combination with gemcitabine.

A low, non-genotoxic, dose (about 1 nM) of ActD has been shown to induce a reversible cytostatic effect in normal proliferating dermal fibroblasts and protect them from the aneuploidy induced by the aurora kinase inhibitor VX - 680 and the toxic effects of gemcitabine [46, 47].

This property of quizartinib conferred marked protection to MPPs in mice receiving fluorouracil or gemcitabine.

In 2013, Abraxane (nanoparticle albumin — bound formulation of paclitaxel) was approved in combination with gemcitabine for metastatic pancreatic canceIn 2013, Abraxane (nanoparticle albumin — bound formulation of paclitaxel) was approved in combination with gemcitabine for metastatic pancreatic cancein combination with gemcitabine for metastatic pancreatic cancer.

In fact, they stressed the fact of quercetin's effectiveness as a single agent against pancreatic cancer tumors, declaring: «Quercetin alone inhibited tumor growth to such an extent that it could not be further enhanced by the addition of gemcitabine.»

Prior to joining Elanco, McGraw practiced as an in - house patent counsel for Eli Lilly and Company in Indianapolis for over 14 years, where she gained experience in global patent portfolio and exclusivity creation and managed the international patent litigation associated with gemcitabine.